Your browser doesn't support javascript.
loading
Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study.
Gkrouzman, Elena; Willis, Rohan; Andrade, Danieli; Tektonidou, Maria G; Pengo, Vittorio; Ruiz-Irastorza, Guillermo; Belmont, H Michael; Fortin, Paul R; Gerosa, Maria; Signorelli, Flavio; Atsumi, Tatsuya; Branch, D Ware; Nalli, Cecilia; Rodriguez-Almaraz, Esther; Petri, Michelle A; Cervera, Ricard; Knight, Jason S; Efthymiou, Maria; Cohen, Hannah; Bertolaccini, Maria Laura; Erkan, Doruk; Roubey, Robert.
Afiliación
  • Gkrouzman E; Division of Rheumatology, University of Massachusetts Chan Medical School, Worcester, Massachusetts. Electronic address: Elena.Gkrouzman@umassmed.edu.
  • Willis R; University of Texas Medical Branch, Galveston, Texas.
  • Andrade D; University of São Paulo, São Paulo, Brazil.
  • Tektonidou MG; National and Kapodistrian University of Athens, Athens, Greece.
  • Pengo V; Padova University Hospital, Padova, Italy.
  • Ruiz-Irastorza G; Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, UPV/EHU, Bizkaia, The Basque Country, Spain.
  • Belmont HM; New York University Langone Medical Center, New York, New York.
  • Fortin PR; CHU de Québec-Université Laval, Quebec City, Quebec, Canada.
  • Gerosa M; University of Milan, Milan, Italy.
  • Signorelli F; Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Atsumi T; Hokkaido University Hospital, Sapporo, Japan.
  • Branch DW; James R. and Jo Scott Research Chair, University of Utah and Intermountain Healthcare, Salt Lake City, Utah.
  • Nalli C; Rheumatology and Clinical Immunology, ASST Spedali Civili; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Rodriguez-Almaraz E; Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Petri MA; Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Cervera R; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
  • Knight JS; Division of Rheumatology, University of Michigan, Ann Arbor, Michigan.
  • Efthymiou M; Haemostasis Research Unit, Department of Hematology, University College London, London, United Kingdom.
  • Cohen H; Haemostasis Research Unit, Department of Hematology, University College London, London, United Kingdom.
  • Bertolaccini ML; King's College London, London, United Kingdom.
  • Erkan D; Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Cornell Medicine, New York, New York.
  • Roubey R; University of North Carolina, Chapel Hill, North Carolina.
Lab Invest ; 103(6): 100147, 2023 06.
Article en En | MEDLINE | ID: mdl-37044248
ABSTRACT
Several antiphospholipid antibody (aPL) profiles ("triple" and lupus anticoagulant [LA] positivity) are associated with a higher risk for clinical manifestations of antiphospholipid syndrome (APS). Further risk is correlated with higher levels of anticardiolipin antibody (aCL) and anti-ß2 glycoprotein-I antibody (aß2GPI), and with aPL persistence. Given that the 3 aPL tests detect partially overlapping sets of antibodies, the primary goal of this study was to characterize the associations among aPL tests using AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) core laboratory data. The APS ACTION Registry includes annually followed adult patients with positive aPL based on the Revised Sapporo Classification Criteria. We analyzed baseline and prospective core laboratory data of the registry for associations among aPL tests using the Spearman rank correlation with Bonferroni-adjusted significance level for multiple comparisons. An aPL Load was calculated based on 6 tests (aCL IgG/IgM/IgA and aß2GPI IgG/IgM/IgA); a receiver operating characteristic curve was used to evaluate the diagnostic performance of the aPL Load in predicting LA positivity. In 351 patients simultaneously tested for LA, aCL, and aß2GPI, the frequency of moderate-to-high (≥40 U) titers of aCL and aß2GPI IgG/IgM/IgA was higher in patients who were positive for LA vs those who were negative. An aPL Load was calculated for each patient to assess the overall aPL burden. For every 1-point increase in the aPL Load, the possibility of a positive LA test increased by 32% (odds ratio, 1.32; 95% CI, 1.2-1.5; P < .001). Based on core laboratory data from a large international registry, most aPL enzyme-linked immunosorbent assay ≥40 U and a high calculated aPL Load combining 6 aPL enzyme-linked immunosorbent assays were predictive of a positive LA. These data suggest that the combined quantitative burden of aPL may provide a mechanistic explanation of a positive LA.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndrome Antifosfolípido Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Lab Invest Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndrome Antifosfolípido Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Lab Invest Año: 2023 Tipo del documento: Article